Advertisement


Hagop M. Kantarjian, MD, on AML: Safety and Efficacy of Guadecitabine

2015 ASH Annual Meeting

Advertisement

Hagop M. Kantarjian, MD, of MD Anderson Cancer Center, discusses a study that compared efficacy and safety results of using 5-day and 10-day regimens of a novel hypomethylating agent in 103 treatment-naïve AML patients who were not candidates for intensive chemotherapy (Abstract 458).



Related Videos

Lymphoma

Nathan Hale Fowler, MD, on Follicular Lymphoma: Ibrutinib Plus Rituximab Study Results

Nathan Hale Fowler, MD, of MD Anderson Cancer Center, discusses a multicenter trial in which ibrutinib plus rituximab was administered to treatment-naive patients with follicular l...

Leukemia

Andrew D. Zelenetz, MD, PhD, on CLL: Idelalisib Plus Bendamustine and Rituximab

Andrew D. Zelenetz, MD, PhD, of Memorial Sloan Kettering Cancer Center, discusses a late-breaking abstract on the superiority of this three-drug combination compared to bendamustin...

Lymphoma

John Leonard, MD, on DLBCL: Results From the Pyramid Trial

John Leonard, MD, of Weill Cornell Medical College, discusses this phase II study of R-CHOP with or without bortezomib in patients with untreated non-germinal center B-cell-like su...

Multiple Myeloma

Sagar Lonial, MD, on Multiple Myeloma: How I Treat Newly Diagnosed Patients

Sagar Lonial, MD, of Emory University School of Medicine, summarizes his educational session on this vital topic.

Lymphoma

Kieron Dunleavy, MD, on Burkitt Lymphoma: Preliminary Report of the DA-EPOCH-R Trial

Kieron Dunleavy, MD, of the National Cancer Institute, discusses a multi-center trial that set out to validate the effectiveness of DA-EPOCH-R-based therapy and whether a risk-adap...

Advertisement

Advertisement



Advertisement